137MO Outcomes of patients (pts) treated with ESCAT I–II targeted therapies (TT) in early phase clinical trials (EPCTs)

TT and next-generation sequencing (NGS) have transformed cancer care, enabling personalized treatment approaches based on tumor molecular profiles. We evaluated outcomes of pts treated with ESCAT 1–2 matched agents in EPCTs within the 360 RESISTANCE (360R) study.